Palatin Technologies, Inc. – AMEX:PTN

Add to watchlist

$0.094

-1.01

-91.52%

Market open

Closed in about 4 hours

-37.29%

month

-37.29%

quarter

-71.61%

year

Market Cap	19.78M
Enterprise value	8.14M

P/E	-0.83
EV/Sales	2.68
EV/EBITDA	-0.25
Price/Sales	9.34
Price/Book	1.73
PEG ratio	0.12
EPS	-3.38

Revenue	N/A
EBITDA	-39.05M
Income	-38.91M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-1380%
Oper. margin	-1055.88%
Gross margin	89.08%
EBIT margin	-1055.88%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Palatin Technologies, Inc. (AMEX:PTN): Profit margin
Jun 2022	770.73K	-12.76M	-1656.54%
Mar 2023	1.19M	-6.99M	-585.28%
Jun 2023	1.76M	-10.71M	-608.11%
Mar 2024	0	-8.43M

Palatin Technologies Financials Estimate

Q Y

Palatin Technologies, Inc. (AMEX:PTN): Analyst Estimates
2028	111.29M	5.66M	5.09%

Analysts Price target
Financials & Ratios estimates

Palatin Technologies, Inc. (AMEX:PTN): Debt to assets
Dec 2022	31976538	15.63M	48.89%
Mar 2023	25608896	16.01M	62.54%
Jun 2023	17939440	15.72M	87.64%
Mar 2024	11406237	9.82M	86.16%

Palatin Technologies, Inc. (AMEX:PTN): Cash Flow
Jun 2022	-7.71M	-37.11K	-24.41K
Mar 2023	-1.40M	-116.87K	-25.31K
Jun 2023	-9.60M	-3.04M	1.00M
Mar 2024	-8.60M	0	9.13M

Palatin Technologies alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Palatin Technologies
Employees

Palatin Technologies, Inc. (AMEX:PTN): Employee count
Aug 2023	33
Sep 2023	33
Oct 2023	33
Nov 2023	34
Dec 2023	34
Jan 2024	34
Feb 2024	34
Mar 2024	34
Apr 2024	34
May 2024	34
Jun 2024	34
Jul 2024	34

Palatin Technologies
Hedge Funds Holdings Q1 2023

0.14% -0.62%

of PTN is owned by hedge funds

19 -14

hedge funds hold PTN stock

318.11K -1.45M

shares is hold by hedge funds

PTN hedge funds holdings changes

Palatin Technologies
Insider Trading

Palatin Technologies, Inc. (AMEX:PTN): Insider trades (number of shares)
Period	Buy	Sel
Dec 2023	0	5198
Mar 2024	0	11700
Apr 2024	6000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	11 Apr 2024	DEVEER ROBERT K JR director director	Common Stock	6,000	$2.12	$12,702
Sale	6 Mar 2024	DEVEER ROBERT K JR director director	Common Stock	1,685	$2	$3,370
Sale	6 Mar 2024	DEVEER ROBERT K JR director director	Common Stock	7,486	$2	$14,972
Sale	6 Mar 2024	DEVEER ROBERT K JR director director	Common Stock	1,808	$2.01	$3,634
Sale	6 Mar 2024	DEVEER ROBERT K JR director director	Common Stock	106	$2.01	$213
Sale	6 Mar 2024	DEVEER ROBERT K JR director director	Common Stock	460	$2.02	$929
Sale	6 Mar 2024	DEVEER ROBERT K JR director director	Common Stock	155	$2.03	$315
Sale	6 Dec 2023	WILLS STEPHEN T officer: Executive VP and CFO/COO officer: Executive VP and CFO/COO	Common Stock	2,807	$2.42	$6,779
Sale	6 Dec 2023	WILLS STEPHEN T officer: Executive VP and CFO/COO officer: Executive VP and CFO/COO	Common Stock	2,191	$2.64	$5,784
Sale	4 Dec 2023	DUNTON ALAN W director director	Common Stock	199	$2.48	$494

PTN insider trading transactions

Palatin Technologies
Earnings Call Transcripts

Quarter	Transcript
Q3 2024 15 May 2024	Q3 2024 Earnings Call Transcript
Q2 2024 15 Feb 2024	Q2 2024 Earnings Call Transcript
Q1 2024 14 Nov 2023	Q1 2024 Earnings Call Transcript
Q4 2023 29 Sep 2023	Q4 2023 Earnings Call Transcript

PTN earnings call transcripts

Palatin Technologies
Executives

Insider	Age	Since	Compensation
Dr. Carl Spana Ph.D. (1962) Co-Founder, Pres, Chief Executive Officer & Director	63		$924,500
Mr. Stephen T. Wills CPA, CPA, MST (1957) Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer & Sec.	68		$851,930

Palatin Technologies
Latest News

Thursday, 19 December 2024
07:30	Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy	prnewswire.com
Monday, 16 December 2024
07:30	Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds	prnewswire.com
Monday, 25 November 2024
07:30	Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis	prnewswire.com
Thursday, 14 November 2024
12:49	Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript	seekingalpha.com
07:30	Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results	prnewswire.com
Friday, 8 November 2024
09:57	Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024	prnewswire.com
Monday, 4 November 2024
07:30	Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024	prnewswire.com
Thursday, 31 October 2024
07:30	Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity	prnewswire.com
Thursday, 24 October 2024
07:30	Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium	prnewswire.com
Wednesday, 23 October 2024
07:30	Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium	prnewswire.com
Monday, 7 October 2024
16:15	Palatin Receives Notice of Non-Compliance from NYSE American	prnewswire.com
Tuesday, 1 October 2024
07:30	Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones	prnewswire.com
Thursday, 26 September 2024
07:30	Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results	prnewswire.com
Monday, 9 September 2024
07:30	Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones	prnewswire.com
Wednesday, 28 August 2024
07:30	FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)	prnewswire.com
Thursday, 22 August 2024
07:30	First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity	prnewswire.com
Friday, 21 June 2024
08:00	Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds	prnewswire.com
Thursday, 20 June 2024
07:30	Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)	prnewswire.com
Wednesday, 12 June 2024
07:30	Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity	prnewswire.com
Monday, 20 May 2024
15:17	Palatin Technologies Upgraded to Buy: What Does It Mean for the Stock?	https://www.benzinga.com
13:01	Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?	zacks.com
Wednesday, 15 May 2024
07:30	Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update	prnewswire.com
Thursday, 9 May 2024
07:30	Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024	PRNewsWire
Tuesday, 9 April 2024
10:01	Palatin (PTN) Up 15% on Results From Dry Eye Disease Study	Zacks Investment Research
Thursday, 15 February 2024
07:49	The 3 Best Penny Stocks to Buy in February 2024	InvestorPlace
Friday, 9 February 2024
07:30	Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024	PRNewsWire
Thursday, 1 February 2024
19:09	7 Analyst-Backed Stocks With Promising 10-Bagger Potential	InvestorPlace
Thursday, 11 January 2024
13:38	3 Penny Stocks to Buy to Unlock 2,500% Upside Potential	InvestorPlace
Saturday, 23 December 2023
17:00	Analysts Say 3 Stocks Have a Combined Upside of 3000%	InvestorPlace
Thursday, 9 November 2023
07:30	Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023	PRNewsWire

Ideas & Opinions

Seeking Alpha 5 Oct 2022

Palatin: Inhibitor Drug With Potential In Several Autoimmune Disorders
Seeking Alpha 23 Feb 2022

Palatin Technologies: A Diamond In The Rough

Frequently Asked Questions (FAQ)

What's the price of Palatin Technologies stock today?

One share of Palatin Technologies stock can currently be purchased for approximately $0.09.
When is Palatin Technologies's next earnings date?

Unfortunately, Palatin Technologies's (PTN) next earnings date is currently unknown.
Does Palatin Technologies pay dividends?

No, Palatin Technologies does not pay dividends.
How much money does Palatin Technologies make?

Palatin Technologies has a market capitalization of 19.78M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 7.49% to 4.49M US dollars.
What is Palatin Technologies's stock symbol?

Palatin Technologies, Inc. is traded on the AMEX under the ticker symbol "PTN".
What is Palatin Technologies's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Palatin Technologies?

Shares of Palatin Technologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Palatin Technologies's key executives?
Palatin Technologies's management team includes the following people:
- Dr. Carl Spana Ph.D. Co-Founder, Pres, Chief Executive Officer & Director(age: 63, pay: $924,500)
- Mr. Stephen T. Wills CPA, CPA, MST Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer & Sec.(age: 68, pay: $851,930)
Is Palatin Technologies founder-led company?

Yes, Palatin Technologies is a company led by its founder Dr. Carl Spana Ph.D..
How many employees does Palatin Technologies have?

As Jul 2024, Palatin Technologies employs 34 workers.
When Palatin Technologies went public?

Palatin Technologies, Inc. is publicly traded company for more then 27 years since IPO on 15 Oct 1997.
What is Palatin Technologies's official website?

The official website for Palatin Technologies is palatin.com.
Where are Palatin Technologies's headquarters?

Palatin Technologies is headquartered at Cedar Brook Corporate Center, Cranbury, NJ.
How can i contact Palatin Technologies?

Palatin Technologies's mailing address is Cedar Brook Corporate Center, Cranbury, NJ and company can be reached via phone at +60 9 495 2200.

Palatin Technologies, Inc.

palatin.com

Exchange:

AMEX

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

+60 9 495 2200

Cedar Brook Corporate Center
Cranbury, NJ 08512

CIK: 0000911216
ISIN: US6960775020
CUSIP: 696077403